A recent study has unveiled a significant advancement in the understanding of diabetic eye disease, potentially transforming treatment approaches. Conducted on mice and backed by Diabetes UK, Moorfields Eye Charity, and Wellcome, this research suggests that future therapies could prevent vision loss before it manifests, rather than merely addressing damage after it occurs.
LRG1: A Key Player in Retinal Damage
The findings, published in Science Translational Medicine, identify a protein named LRG1 as a crucial factor initiating early retinal damage in diabetes. Researchers observed that LRG1 causes excessive tightening of cells surrounding the eye's smallest blood vessels, leading to reduced oxygen supply to the retina. This process triggers a chain reaction that can culminate in long-term vision impairment.
In experiments with diabetic mouse models, scientists successfully inhibited LRG1 activity, preventing early retinal damage and preserving normal eye function. Dr. Giulia De Rossi from the UCL Institute of Ophthalmology emphasized the importance of this discovery, stating that targeting LRG1 could enable protective measures against vision loss before irreversible damage occurs, benefiting millions with diabetes.
Limitations of Current Treatments
Diabetic retinopathy affects individuals with both type 1 and type 2 diabetes, with treatments often commencing only after symptoms like blurred vision appear. By this time, significant damage may have already occurred. Current therapies primarily focus on another protein, VEGF, which only benefits about half of patients and fails to reverse existing damage.
The research indicates that LRG1 initiates eye damage much earlier than VEGF, making it a promising target for new therapies. A treatment aimed at inhibiting LRG1 could potentially intervene earlier and halt disease progression.
Innovative Treatment Options on the Horizon
Dr. Faye Riley from Diabetes UK, who contributed to the research funding, noted that nearly one-third of adults with diabetes show signs of retinopathy, underscoring the significance of this research. By pinpointing the root cause of early damage, this study opens new avenues for treatment, offering hope for the increasing number of individuals with diabetes globally.
The UCL research team has developed a drug targeting LRG1, which has shown promise in preliminary studies and is currently undergoing further preclinical research, with plans for human clinical trials on the horizon.
Researchers believe this therapy could not only prevent the onset of diabetic retinopathy but also aid those with more advanced stages of the disease, as LRG1 continues to play a role in ongoing damage.
Years of Dedicated Research
This breakthrough builds on years of investigation by the UCL Institute of Ophthalmology into LRG1's role in ocular diseases. Co-authors Professors John Greenwood and Stephen Moss were pioneers in identifying LRG1's involvement in eye conditions and established Senya Therapeutics, a spinout company aimed at developing targeted therapies.
Professor Greenwood expressed excitement about the study's implications for clinical applications, while Professor Moss highlighted the readiness of their LRG1 therapeutic for clinical trials, offering a new treatment option for patients, particularly in the early stages of the disease.
Hope for Diabetic Patients
Dr. Ailish Murray from Moorfields Eye Charity remarked on the challenge of detecting early diabetic retinopathy, which often leads to irreversible damage. This research represents a crucial step towards preventing such outcomes, with the potential to safeguard the vision of millions now and in the future.
Morag Foreman from Wellcome noted that this breakthrough illuminates a promising path for treating diabetic eye disease, showcasing the impact of early scientific research in advancing medical treatments.